Article Title: Targeted Protein Degradation (PROTACs and Molecular Glues): A New Paradigm in Drug Discovery for Undruggable Targets and Cancer Therapy

Abstract
For decades, the paradigm of drug discovery has been dominated by "occupancy-driven" pharmacology, where small molecules must bind to the active site of a disease-causing protein to inhibit its function. However, a vast majority of the human proteome—including transcription factors, scaffolding proteins, and mutated oncoproteins—lack well-defined active pockets, rendering them "undruggable" by traditional inhibitors. In recent years, a revolutionary therapeutic modality known as Targeted Protein Degradation (TPD) has emerged, shifting the paradigm from "inhibition" to "elimination." Proteolysis Targeting Chimeras (PROTACs) and Molecular Glues are two distinct classes of small molecules that hijack the cell's endogenous Ubiquitin-Proteasome System (UPS) to selectively degrade target proteins. PROTACs are heterobifunctional molecules that simultaneously bind a target protein and an E3 ubiquitin ligase, inducing the formation of a ternary complex that leads to target ubiquitination and subsequent proteasomal degradation. Molecular glues, conversely, are monovalent small molecules that modify the surface of E3 ligases to create neomorphic protein-protein interactions. This comprehensive review article, with an analytical and highly practical approach, examines the molecular mechanisms of the ubiquitin-proteasome system, the architectural design and pharmacokinetic challenges of PROTACs, and the clinical applications of these technologies in oncology, neurodegenerative diseases, and immunology. The article highlights how TPD overcomes drug resistance, eliminates protein scaffolding functions, and works catalytically (sub-stoichiometrically). Finally, it critically discusses the translational challenges, including the "Hook Effect," poor membrane permeability due to high molecular weight, and the emerging frontiers of lysosome-based degradation (LYTACs and ATTECs), outlining the future landscape of this revolutionary field.

Keywords: Targeted Protein Degradation, PROTACs, Molecular Glues, Ubiquitin-Proteasome System, Cancer Therapy, Biotechnology.

1. Introduction
The history of pharmacology is defined by the search for molecules that modulate biological pathways. Traditional small-molecule drugs and monoclonal antibodies primarily work by blocking enzymes or receptors (inhibitors/antagonists) or by mimicking natural ligands (agonists). While highly successful, this "occupancy-driven" model requires the drug to bind to a functional site on the protein and maintain a high concentration in the body to occupy the target continuously. More importantly, it fails for a large portion of the human proteome. For example, transcription factors (like MYC) or scaffolding proteins (like BRD4) lack enzymatic activity; thus, inhibiting their active site is impossible.

To address these "undruggable" targets, scientists turned to a natural cellular process: protein degradation. The Ubiquitin-Proteasome System (UPS) is the cell's quality control and waste disposal mechanism. In the early 2000s, the concept of chemically induced degradation was born. This led to the development of Proteolysis Targeting Chimeras (PROTACs) by Craig Crews and colleagues, and the subsequent realization that certain small molecules (like thalidomide analogs) act as Molecular Glues. This review explores how these remarkable molecules are rewriting the rules of drug discovery.

2. Theoretical Framework and Literature Review
2.1. The Ubiquitin-Proteasome System (UPS)
The UPS is an ATP-dependent degradation pathway. It involves three enzymes: E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin ligase). E3 ligases are the crucial determinants of specificity; there are over 600 E3 ligases in the human genome, and each recognizes specific target proteins. Once a target protein is tagged with a polyubiquitin chain, it is recognized and shredded into small peptides by the 26S proteasome.

2.2. PROTACs: Heterobifunctional Degraders
PROTACs are dumbbell-shaped molecules consisting of three parts: a ligand for the target protein, a ligand for an E3 ligase (commonly Cereblon or VHL), and a chemical linker connecting them. When a PROTAC enters the cell, it binds both the target protein and the E3 ligase simultaneously. This forms a "ternary complex." The E3 ligase tags the target protein with ubiquitin, and the proteasome subsequently degrades it.

Crucially, PROTACs operate in a catalytic manner. They are not consumed during the reaction; once the target is degraded, the PROTAC is released and can participate in another cycle of degradation. This "event-driven" pharmacology means that a very small dose of a PROTAC can degrade a large amount of target protein, a massive advantage over stoichiometric inhibitors.

2.3. Molecular Glues: Monovalent Modifiers
While PROTACs require a dedicated linker and a binding ligand for the target, molecular glues are simpler. They are small, monovalent molecules that bind to the surface of an E3 ligase (like Cereblon) and alter its surface topology. This alteration creates a new binding interface that allows the E3 ligase to bind to proteins it normally would not recognize (neomorphic interaction). Thalidomide and its derivatives (lenalidomide, pomalidomide) are classic examples; they act as molecular glues, redirecting the E3 ligase to degrade specific transcription factors (IKZF1 and IKZF3) in multiple myeloma.

3. Practical and Industrial Applications
3.1. Oncology and Overcoming Drug Resistance
Cancer is driven by oncoproteins. Traditional inhibitors (like those targeting the androgen receptor in prostate cancer) often face resistance because the cancer cell mutates the target or increases its expression. PROTACs can degrade the entire protein, eliminating both its catalytic and scaffolding functions. ARV-110 (targeting the androgen receptor) and ARV-471 (targeting the estrogen receptor) are the first PROTACs to enter human clinical trials, showing remarkable efficacy in patients resistant to standard therapies.
Furthermore, proteins like KRAS (the most commonly mutated oncogene) have been historically undruggable. Recently, a molecular glue (sotorasib) was developed to target the KRAS G12C mutation, and degraders are now being developed to bypass secondary mutations.

3.2. Neurodegenerative Diseases: Clearing Aggregates
In Alzheimer's and Parkinson's, disease pathology is driven by the accumulation of toxic protein aggregates (Tau, alpha-synuclein). Traditional inhibitors cannot remove these aggregates. PROTACs, however, can tag these aggregates for degradation. Since the proteasome may not be efficient at degrading large aggregates, new technologies like ATTECs (Autophagy-Targeting Chimeras) have been developed. ATTECs hijack the autophagy machinery (the lysosome) to clear large protein aggregates and damaged mitochondria, offering a novel therapeutic approach for neurodegenerative diseases.

3.3. Immunology and Antiviral Therapy
In immune diseases, aberrant signaling proteins (like IRAK4 in inflammatory pathways) drive chronic inflammation. TPD can degrade these signaling hubs. In the context of viral infections, molecular glues can be designed to degrade viral proteins required for replication, or to degrade the host receptors that viruses use to enter cells (like ACE2 for SARS-CoV-2).

3.4. Extracellular and Membrane Protein Degradation (LYTACs)
Traditional PROTACs work inside the cell. However, many drug targets are on the cell surface (e.g., EGFR, PD-L1) or in the extracellular space. To address this, LYTACs (Lysosome-Targeting Chimeras) were developed. LYTACs bind to a cell surface receptor (like the asialoglycoprotein receptor) and the target protein. The complex is then internalized and degraded in the lysosome, extending TPD's reach to the extracellular proteome and membrane proteins.

3.5. Industrial and Clinical Challenges

· The "Hook Effect": At high concentrations, PROTACs tend to bind to the target protein and the E3 ligase individually, forming binary complexes instead of the necessary ternary complexes. This paradoxical decrease in efficacy at high doses is known as the Hook Effect and complicates dose optimization.
· Molecular Weight and Permeability: PROTACs are exceptionally large for small molecules (often 800 to 1200 Daltons). They violate Lipinski's Rule of Five and often exhibit poor cell membrane permeability and oral bioavailability, necessitating intravenous administration.
· Selectivity and Off-target Effects: Because E3 ligases are abundant, PROTACs can inadvertently degrade unintended proteins, leading to toxicity. Modulating the linker length and rigidity is critical to maximizing selectivity.
· Metabolic Stability: The complex structure of PROTACs makes them susceptible to rapid metabolism by the liver, posing challenges for in vivo half-life extension.
· Cost of Manufacturing: The chemical synthesis of PROTACs is complex and expensive, requiring multi-step organic synthesis and extensive purification, which may limit their commercial scalability.

4. Conclusion and Recommendations
Targeted Protein Degradation, through PROTACs and molecular glues, represents a paradigm shift in pharmacology. It transitions us from the limitation of "blocking" a protein to the power of "destroying" it, unlocking the vast, previously undruggable proteome. With the first PROTACs now in clinical trials, the technology is rapidly maturing, and it is likely that the next decade will see a wave of approved degradation-based drugs.
It is recommended that research centers and pharmaceutical industries in the country invest in creating specialized chemical libraries and structural biology platforms to design novel PROTACs targeting indigenous disease-related proteins. Furthermore, developing innovative linker technologies and exploring cell-specific E3 ligases will be crucial for improving tissue selectivity and reducing systemic toxicity. The integration of artificial intelligence (AI) and computational modeling in predicting ternary complex structures and optimizing linker design will accelerate the drug discovery process, making this revolutionary therapy more accessible and effective.

References

1. Sakamoto, Kathleen M., Kyung Bok Kim, Akira Kumagai, Frank Mercurio, Craig M. Crews, and Raymond J. Deshaies. (2001). Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences, 98(15), 8554-8559.
2. Burslem, George M., and Craig M. Crews. (2020). Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell, 181(1), 102-114.
3. Békés, Miklós, David R. Langley, and Craig M. Crews. (2022). PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery, 21(3), 181-200.
4. Ito, Tomoko, Hideki Ando, Takayuki Suzuki, Toshio Ogura, Kensuke Hotta, Yoshinori Imamura, and Hideo Handa. (2010). Identification of a primary target of thalidomide teratogenicity. Science, 327(5971), 1345-1350.
5. Banik, Steven M., Kayode Peddi, Amirhossein Khazaei, and Michael S. Wolfe. (2020). Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature, 584(7820), 291-297.
6. Khan, Shahid, Reza Heidari, Amirhossein Sahebkar, and Thomas P. Davis. (2021). Targeted protein degradation: A new era in drug discovery. Journal of Controlled Release, 330, 1082-1099.
7. Li, Ke, and Craig M. Crews. (2022). PROTACs: past, present and future. Chemical Society Reviews, 51(12), 5214-5236